VC-Backed Bay Area Biotech Files Plans For $80M IPO
Gritstone Oncology, a venture capital-backed biotechnology company that focuses its research on cancer-fighting immunotherapies, filed plans Thursday for an $80 million initial public offering steered by Latham & Watkins LLP....To view the full article, register now.
Already a subscriber? Click here to view full article